TP53, NKX2-1, CDK4, MYC and RB1 were identified as predictive biomarkers...Specifically, gefitinib-favoring biomarkers include TP53 exon4/5 mutations (interaction HR [iHR] 0.33, 95% CI 0.12-0.93, p = 0.035), and copy number gain of NKX2-1 (iHR 0.26, 95% CI 0.098-0.68, p = 0.006), CDK4 (iHR 0.14, 95% CI 0.025-0.77, p = 0.024) and MYC (iHR 0.10, 95% CI 0.011-0.98, p = 0.048).